ATENTS THA

06/22/2007 03 FC:1814

PTO/SB/26 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAUMED TO OBVIATE A DOUBLE TO A DOUBLE TO BE A DOU

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

TERMINAL DISCLAIMER TO OBVIATE REJECTION OVER A "PRI		Docket Number (Optional)
In re Application of: Unchalee Kositprapa		
Application No.: 10/634,321		
Filed: August 4, 2003		
For: Pharmaceutical Formulation		
The owner*, Andrx Pharmaceuticals, LLC except as provided below, the terminal part of the statutory the expiration date of the full statutory term prior patent No and 173, and as the term of said prior patent is presently signated on the instant application shall be enforceable only agreement runs with any patent granted on the instant application.	6,174,548 as the term of said shortened by any terminal disclaimer. The c for and during such period that it and the p	application which would extend beyond prior patent is defined in 35 U.S.C. 154 wher hereby agrees that any patent so rior patent are commonly owned. This
In making the above disclaimer, the owner does not disclain would extend to the expiration date of the full statutory term patent is presently shortened by any terminal disclaimer," in expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction;	as defined in 35 U.S.C. 154 and 173 of the	t granted on the instant application that prior patent, "as the term of said prior
is statutorily disclaimed in whole or terminally disclaime has all claims canceled by a reexamination certificate; is reissued; or		
is in any manner terminated prior to the expiration of its	s tuil statutory term as presently shortened t	by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business/organizati etc.), the undersigned is empowered to act on behalf.		, government agency,
I hereby declare that all statements made herein belief are believed to be true; and further that these stater made are punishable by fine or imprisonment, or both, und statements may jeopardize the validity of the application or a	nents were made with the knowledge that der Section 1001 of Title 18 of the United	willful false statements and the like so
2. The undersigned is an attorney or agent of record.	Reg. No. 56,878	
Make	PA	
		June 18, 2007
	Signature	Date
IDEMESS1 00000024 10634321	Matthew J. Solow	
130.00 OP	Typed or printed name	
•		212-302-8989
		Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) inc	cluded.	
	n may become public. Credit card information and authorization	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.